ArriVent appoints Kristine Peterson to Board; she joins Compensation Committee

ArriVent BioPharma, Inc.

Kristine Peterson appointed as Class III director effective April 20, 2024, until 2027 annual meeting.
Appointed to Compensation Committee on July 3, 2024.
Received option grant with $352,500 fair value, vesting over three years; annual cash retainer of $45,000 prorated.
Peterson brings >30 years biopharma experience; former CEO of Valeritas, exec roles at J&J and BMS.
Currently on boards of Immunocore and Enanta; deemed independent under Nasdaq rules.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kristine Peterson

Director

AVBP · ArriVent BioPharma, Inc.

Effective: 2024-04-20
Filed: July 9, 2024, 7:59 PM ET

On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately (the “Effective Date”).

View on SEC.gov

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-078585

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.